Navigation Links
Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
Date:1/9/2008

PRINCETON, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Novo Nordisk, a healthcare company with an 84-year history of innovation and achievement in diabetes care, today announced the appointment of Alan C. Moses, M.D. as vice president, chief medical officer worldwide. Moses is currently the chief medical officer of Novo Nordisk Inc., the company's U.S. affiliate.

"Alan has the unique talent to integrate the science of discovery with new drug development -- a critical asset that will deepen Novo Nordisk's leadership position in changing diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer for Novo Nordisk A/S. "The broadening of Novo Nordisk's diabetes therapeutic portfolio with the development of liraglutide and other novel molecules in the pipeline, and the increasing importance of the U. S. to the Novo Nordisk business, requires a leader with clinical and research expertise to assume the role of chief medical officer."

In the newly expanded role, Moses will work closely with senior colleagues in Denmark to serve as the principle voice of clinical science for the company worldwide, providing clinical and medical affairs expertise.

"Novo Nordisk and the diabetes community in the U.S. have been fortunate to have Alan lead the efforts for the company in changing diabetes, and now, with his expanded responsibilities, the world will benefit from Alan's passion for research and advocacy for finding better ways for people to live with the disease," said Dr. Henrik Rasmussen, vice president of clinical development, medical and regulatory affairs, Novo Nordisk Inc.

Moses was formerly senior vice president and chief medical officer at the Joslin Diabetes Center and joined Novo Nordisk in April 2004 as associate vice president of medical affairs and since then has also assumed responsibility for clinical research in diabetes. Prior to joining Novo Nordisk, Dr. Moses spent 23 years at Harvard Medical School-affiliated institutions where he rose to the rank of Professor of Medicine. He has written more than 100 peer- reviewed articles on the treatment of diabetes and has been recognized both locally and nationally for his research in diabetes and growth factors.

Moses received a Bachelor of Science from Duke University and a Medical Doctorate from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, the National Institutes of Health in Bethesda, Md., and Tufts-New England Medical Center in Boston. He is board certified by the American Board of Internal Medicine and has a subspecialty certification in Endocrinology and Metabolism.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
2. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
3. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
6. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
7. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
10. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
11. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... NBIX ) today announced its financial results for the quarter ... --> For the fourth quarter of 2015, the ... per share, compared to a net loss of $19.4 million, or ... the year ended December 31, 2015, the Company reported a net ... to a net loss of $60.5 million, or $0.81 loss per ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit organization ... researched, developed, marketed and made accessible to patients around the ... had named the publication of the Good Pharma ... publication is also featured as one of BMJ Open ... last year that are most frequently read. Ed ...
(Date:2/11/2016)... (PRWEB) , ... February 11, ... ... business-to-business publication dedicated to delivering cutting-edge information focused on the development and ... Sciences to become a premier sponsor of the 2016 BioProcess International Awards ...
Breaking Biology Technology:
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):